Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-09-08 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
监事会关于公司第三期限制性股票激励计划预留授予激励对象名单的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Supervisory Board regarding the verification of the reserved grant list for the company's third restricted stock incentive plan. It references compliance with stock incentive management regulations, stock exchange listing rules, and company articles of association. The content focuses on the approval and verification of stock incentive recipients, which is related to executive compensation and stock incentive plans. This type of document is typically classified under Remuneration Information, as it deals with stock-based compensation plans and related approvals rather than financial results, governance structure, or general announcements. The document length is short and contains substantive content about the incentive plan approval, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the best fit is Remuneration Information (DEF 14A).
2023-09-08 Chinese
关于第八届董事会第六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the sixth meeting of the eighth board of directors of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the approval of a stock incentive plan involving restricted stock grants to incentive recipients. The document includes voting results and references related announcements published elsewhere. It is a formal disclosure of board decisions, specifically about management and board matters, rather than a full report or financial statement. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report itself but an announcement of board resolutions, confirming the classification.
2023-09-08 Chinese
中国国际金融股份有限公司关于安徽安科生物工程（集团）股份有限公司第三期限制性股票激励计划预留授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to the "Third Restricted Stock Incentive Plan" of Anhui Anke Biological Engineering (Group) Co., Ltd. It discusses the approval procedures, grant conditions, and details of the restricted stock incentive plan, including the reserved grant of restricted stocks. The document is issued by China International Capital Corporation Limited as the independent financial advisor. It contains detailed financial advisory opinions and legal compliance statements related to the stock incentive plan. This type of document is a standalone advisory report on a specific financial incentive plan, not a full annual report, earnings release, or regulatory announcement. It fits the category of an Audit Report / Information (AR) as it provides an independent financial advisor's report on a corporate stock incentive plan, including compliance and fairness opinions, which is typical for AR filings. The document length (8263 characters) and content confirm it is a full report, not just an announcement or certification, so it is not RPA or RNS. FY 2023
2023-09-08 Chinese
关于第八届监事会第五次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board (监事会) of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the resolutions passed in the fifth meeting of the eighth supervisory board, specifically regarding the approval of granting reserved restricted stock to incentive recipients under the company's third restricted stock incentive plan. The document includes voting results and compliance statements with relevant laws and regulations. It is not a full financial report, audit report, or earnings release, nor is it a notice of dividend, capital change, or management change. It is a regulatory announcement about a board meeting decision related to stock incentives. Given the nature and length (915 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-08 Chinese
安徽天禾律师事务所关于安徽安科生物工程（集团）股份有限公司第三期限制性股票激励计划预留授予相关事项之法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's third restricted stock incentive plan reserved grant matters. It details the legal compliance, approvals, authorizations, and conditions related to the stock incentive plan. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion supporting a corporate action related to stock incentives. It is not an announcement of voting results or a proxy solicitation. It is a specialized legal opinion document related to management and governance matters, specifically about stock incentive plans. Therefore, it fits best under Board/Management Information (MANG) as it relates to management decisions and board approvals on stock incentive plans.
2023-09-08 Chinese
第三期限制性股票激励计划预留授予激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of reserved grant recipients under a restricted stock incentive plan, detailing names, positions, and stock quantities for middle management and core technical personnel. It is issued by the company's board and dated September 8, 2023. The content focuses on stock incentive allocations to employees rather than financial results, governance rules, or meeting materials. It is not a full report but an announcement of stock incentive allocations to specific individuals. This type of document aligns with announcements related to share-based compensation or capital changes involving stock incentives. Given the nature of the content, it best fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or stock-related capital changes such as restricted stock plans. The document length is about 2700 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is SHA with high confidence.
2023-09-08 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.